Stay updated on Sitravatinib Combo in Clear-Cell RCC Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo in Clear-Cell RCC Clinical Trial page.

Latest updates to the Sitravatinib Combo in Clear-Cell RCC Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing Texas as a site; removed the HHS Vulnerability Disclosure and the Texas Locations entry.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe publication status text updated to indicate auto-fill from PubMed and the revision version updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedNotice about government funding and operating status was removed from the page. This does not affect the study details, eligibility criteria, or how to participate.SummaryDifference0.4%

- Check61 days agoChange DetectedNo significant changes to the study record are evident; the page content and major sections appear unchanged.SummaryDifference0.5%

- Check83 days agoChange DetectedUpdated the page to v3.2.0 and added a government-operating-status notice with links; removed the previous v3.1.0 reference.SummaryDifference5%

- Check90 days agoChange DetectedTerm naming updated from 'Clear cell renal carcinoma' to 'Clear cell carcinoma of kidney' with a version bump to v3.1.0.SummaryDifference0.4%

Stay in the know with updates to Sitravatinib Combo in Clear-Cell RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo in Clear-Cell RCC Clinical Trial page.